Clene Nanomedicine, researching the use of gold atoms to slow ALS progression, nets $42.5M Series D
A biopharma that uses gold to develop treatments for neurodegenerative diseases just got a little bit richer.
Clene Nanomedicine pulled in $42.5 million in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
